Patents by Inventor Ralf Jörg Hosse

Ralf Jörg Hosse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof
    Publication number: 20160075795
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: May 26, 2015
    Publication date: March 17, 2016
    Applicant: Roche GlycArt AG
    Inventors: Ekkehard MÖSSNER, Thomas U. Hofer, Ralf Jörg Hosse, Pablo Umana
  • Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof
    Patent number: 9068008
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: June 30, 2015
    Assignee: Roche Glycart AG
    Inventors: Ekkehard Mössner, Thomas U. Hofer, Ralf Jörg Hosse, Pablo Umaña
  • Targeted immunoconjugates
    Patent number: 8945571
    Abstract: The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: February 3, 2015
    Assignee: Roche GlyeArt AG
    Inventors: Ekkehard Mössner, Ralf Jörg Hosse, Pablo Umaña, Michela Silacci-Melkko
  • Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof
    Publication number: 20110104148
    Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
    Type: Application
    Filed: August 31, 2010
    Publication date: May 5, 2011
    Applicant: Roche GlycArt AG
    Inventors: Ekkehard MÖSSNER, Thomas U. HOFER, Ralf Jörg HOSSE, Pablo UMAÑA
  • TARGETED IMMUNOCONJUGATES
    Publication number: 20110064751
    Abstract: The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Application
    Filed: August 17, 2010
    Publication date: March 17, 2011
    Applicant: Roche GlycArt AG
    Inventors: Ekkehard Mössner, Ralf Jörg Hosse, Pablo Umaña, Michela Silacci-Melkko